SEC61A2

Summary

SEC61A2 (SEC61 translocon subunit alpha 2, HGNC:17702) is a protein-coding gene on chromosome 10p14, encoding Protein transport protein Sec61 subunit alpha isoform 2 (Q9H9S3). Component of SEC61 channel-forming translocon complex that mediates transport of signal peptide-containing precursor polypeptides across the endoplasmic reticulum (ER).

The protein encoded by this gene has similarity to a mouse protein which suggests a role in the insertion of secretory and membrane polypeptides into the endoplasmic reticulum. It may also be required for the assembly of membrane and secretory proteins. Alternative splicing results in multiple transcript variants.

Source: NCBI Gene 55176 — RefSeq curated summary.

At a glance

• Clinical variants (ClinVar): 43 total
• Phenotypes (HPO): 1
• MANE Select transcript: NM_018144

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:17702
Approved symbol	SEC61A2
Name	SEC61 translocon subunit alpha 2
Location	10p14
Locus type	gene with protein product
Status	Approved
Aliases	FLJ10578
Ensembl gene	ENSG00000065665
Ensembl biotype	protein_coding
OMIM	618271
Entrez	55176

Gene structure

Transcript identifiers

Ensembl transcripts: 15 — 11 protein_coding, 2 protein_coding_CDS_not_defined, 2 nonsense_mediated_decay

ENST00000298428, ENST00000304267, ENST00000379017, ENST00000379020, ENST00000379033, ENST00000379051, ENST00000418772, ENST00000419021, ENST00000441368, ENST00000457034, ENST00000466451, ENST00000472221, ENST00000475268, ENST00000495368, ENST00000905219

RefSeq mRNA: 3 — MANE Select: NM_018144 NM_001142627, NM_001142628, NM_018144

CCDS: CCDS44358, CCDS44359, CCDS7088

Canonical transcript exons

ENST00000298428 — 12 exons

Exon	Start	End
ENSE00001832114	12164268	12165407
ENSE00003480870	12143117	12143195
ENSE00003493408	12149595	12149726
ENSE00003514961	12155778	12155931
ENSE00003519327	12156907	12157067
ENSE00003549157	12133241	12133308
ENSE00003585386	12157908	12158105
ENSE00003588559	12149852	12149961
ENSE00003663429	12136105	12136170
ENSE00003676964	12162213	12162289
ENSE00003680481	12129677	12129794
ENSE00003681188	12160930	12161121

Expression profiles

Bgee: expression breadth ubiquitous, 213 present calls, max score 93.23.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 7.1076 / max 63.8824, expressed in 1637 samples.

FANTOM5 promoters (3 alternative TSS)

Promoter ID	TPM avg	Samples expressed
103905	6.6678	1621
103906	0.3713	172
103907	0.0685	17

Top tissues by expression

277 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
cortical plate	UBERON:0005343	93.23	gold quality
sperm	CL:0000019	92.94	gold quality
C1 segment of cervical spinal cord	UBERON:0006469	92.59	gold quality
cerebellar hemisphere	UBERON:0002245	92.24	gold quality
right hemisphere of cerebellum	UBERON:0014890	92.22	gold quality
cerebellar cortex	UBERON:0002129	92.13	gold quality
spinal cord	UBERON:0002240	91.35	gold quality
prefrontal cortex	UBERON:0000451	91.17	gold quality
anterior cingulate cortex	UBERON:0009835	91.04	gold quality
Brodmann (1909) area 9	UBERON:0013540	91.02	gold quality
endothelial cell	CL:0000115	91.00	gold quality
cingulate cortex	UBERON:0003027	90.95	gold quality
male germ cell	CL:0000015	90.83	gold quality
right frontal lobe	UBERON:0002810	90.81	gold quality
cerebellum	UBERON:0002037	90.65	gold quality
dorsolateral prefrontal cortex	UBERON:0009834	90.54	gold quality
neocortex	UBERON:0001950	89.86	gold quality
frontal cortex	UBERON:0001870	89.69	gold quality
frontal lobe	UBERON:0016525	89.69	gold quality
hypothalamus	UBERON:0001898	89.62	gold quality
cerebral cortex	UBERON:0000956	89.23	gold quality
ventricular zone	UBERON:0003053	89.19	gold quality
right testis	UBERON:0004534	89.19	gold quality
left testis	UBERON:0004533	89.16	gold quality
amygdala	UBERON:0001876	88.73	gold quality
nucleus accumbens	UBERON:0001882	88.66	gold quality
telencephalon	UBERON:0001893	88.64	gold quality
caudate nucleus	UBERON:0001873	88.46	gold quality
middle temporal gyrus	UBERON:0002771	88.46	gold quality
brain	UBERON:0000955	88.43	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	4.20

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

65 targeting SEC61A2, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-3646	100.00	73.56	5283
HSA-MIR-12118	100.00	65.88	1270
HSA-MIR-30A-5P	100.00	76.31	3233
HSA-MIR-30B-5P	100.00	76.29	3248
HSA-MIR-30C-5P	100.00	76.29	3248
HSA-MIR-30D-5P	100.00	76.32	3233
HSA-MIR-30E-5P	100.00	76.32	3242
HSA-MIR-548N	99.98	71.94	4170
HSA-MIR-12136	99.98	72.81	5713
HSA-MIR-19A-3P	99.98	75.33	2762
HSA-MIR-19B-3P	99.98	75.44	2754
HSA-MIR-3173-3P	99.98	66.49	1217
HSA-MIR-6891-5P	99.98	66.53	1372
HSA-MIR-1305	99.91	71.43	3443
HSA-MIR-7845-5P	99.88	64.88	771
HSA-MIR-4447	99.85	67.81	2900
HSA-MIR-765	99.84	68.24	2442
HSA-MIR-4698	99.84	71.41	4303
HSA-MIR-4495	99.82	72.08	3080
HSA-MIR-2052	99.79	69.37	2031
HSA-MIR-204-5P	99.79	71.62	2439
HSA-MIR-211-5P	99.79	71.65	2440
HSA-MIR-11181-3P	99.75	66.38	2205
HSA-MIR-92A-2-5P	99.75	67.01	2164
HSA-MIR-7856-5P	99.75	69.99	2901
HSA-MIR-4755-5P	99.71	70.34	2716
HSA-MIR-5006-3P	99.71	70.26	2728
HSA-MIR-3714	99.71	70.74	2671
HSA-MIR-580-3P	99.67	69.23	1841
HSA-MIR-6762-3P	99.66	66.94	1188

Cross-species orthologs

4 orthologs

Organism	Symbol	Gene ID
mus_musculus	Sec61a2	ENSMUSG00000025816
rattus_norvegicus	Sec61a2	ENSRNOG00000023278
drosophila_melanogaster	Sec61alpha	FBGN0086357
caenorhabditis_elegans		WBGENE00013311

Paralogs (1): SEC61A1 (ENSG00000058262)

Protein

Protein identifiers

Protein transport protein Sec61 subunit alpha isoform 2 — Q9H9S3 (reviewed: Q9H9S3)

All UniProt accessions (10): Q9H9S3, A6NIF9, A6NK38, C9JJV4, F2Z2C7, F8W776, H7C069, H7C1Q9, H7C1S8, Q8TC24

UniProt curated annotations — full annotation on UniProt →

Function. Component of SEC61 channel-forming translocon complex that mediates transport of signal peptide-containing precursor polypeptides across the endoplasmic reticulum (ER). Forms a ribosome receptor and a gated pore in the ER membrane, both functions required for cotranslational translocation of nascent polypeptides.

Subunit / interactions. The SEC61 channel-forming translocon complex consists of channel-forming core components SEC61A1, SEC61B and SEC61G and different auxiliary components such as SEC62 and SEC63.

Subcellular location. Endoplasmic reticulum membrane.

Similarity. Belongs to the SecY/SEC61-alpha family.

Isoforms (3)

UniProt ID	Names	Canonical?
Q9H9S3-1	1	yes
Q9H9S3-2	2
Q9H9S3-3	3

RefSeq proteins (3): NP_001136099, NP_001136100, NP_060614* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR002208	SecY/SEC61-alpha	Family
IPR019561	Translocon_Sec61/SecY_plug_dom	Domain
IPR023201	SecY_dom_sf	Homologous_superfamily
IPR030659	SecY_CS	Conserved_site

Pfam: PF00344, PF10559

UniProt features (27 total): topological domain 11, transmembrane region 10, sequence conflict 3, splice variant 2, chain 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9H9S3-F1	72.77	0.00

Function

Pathways and Gene Ontology

Reactome pathways

8 pathways

ID	Pathway
R-HSA-1236974	ER-Phagosome pathway
R-HSA-1799339	SRP-dependent cotranslational protein targeting to membrane
R-HSA-1236975	Antigen processing-Cross presentation
R-HSA-1280218	Adaptive Immune System
R-HSA-168256	Immune System
R-HSA-392499	Metabolism of proteins
R-HSA-72766	Translation
R-HSA-983169	Class I MHC mediated antigen processing & presentation

MSigDB gene sets: 154 (showing top): RODRIGUES_THYROID_CARCINOMA_POORLY_DIFFERENTIATED_UP, REACTOME_ADAPTIVE_IMMUNE_SYSTEM, GOBP_INTRACELLULAR_PROTEIN_TRANSPORT, REACTOME_CLASS_I_MHC_MEDIATED_ANTIGEN_PROCESSING_PRESENTATION, GOBP_PROTEIN_TARGETING, GOBP_ESTABLISHMENT_OF_PROTEIN_LOCALIZATION_TO_ENDOPLASMIC_RETICULUM, GOBP_ESTABLISHMENT_OF_PROTEIN_LOCALIZATION_TO_ORGANELLE, MARTINEZ_RB1_TARGETS_UP, GOBP_PROTEIN_TARGETING_TO_MEMBRANE, GOBP_ESTABLISHMENT_OF_PROTEIN_LOCALIZATION_TO_MEMBRANE, AAAGGGA_MIR204_MIR211, DODD_NASOPHARYNGEAL_CARCINOMA_UP, SHAFFER_IRF4_TARGETS_IN_ACTIVATED_DENDRITIC_CELL, GOBP_PROTEIN_TRANSMEMBRANE_TRANSPORT, RASHI_RESPONSE_TO_IONIZING_RADIATION_6

GO Biological Process (3): SRP-dependent cotranslational protein targeting to membrane, translocation (GO:0006616), post-translational protein targeting to membrane, translocation (GO:0031204), protein transport (GO:0015031)

GO Molecular Function (4): signal sequence receptor activity (GO:0005048), transmembrane protein transporter activity (GO:0008320), ribosome binding (GO:0043022), protein binding (GO:0005515)

GO Cellular Component (4): Sec61 translocon complex (GO:0005784), endoplasmic reticulum (GO:0005783), endoplasmic reticulum membrane (GO:0005789), membrane (GO:0016020)

Reactome top-level categories

Rollup of top-6 pathways:

Category	Pathways
Antigen processing-Cross presentation	1
Translation	1
Class I MHC mediated antigen processing & presentation	1
Immune System	1
Metabolism of proteins	1
Adaptive Immune System	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
intracellular protein transmembrane transport	2
SRP-dependent cotranslational protein targeting to membrane	1
post-translational protein targeting to endoplasmic reticulum membrane	1
transport	1
intracellular protein localization	1
establishment of protein localization	1
molecular_function	1
macromolecule transmembrane transporter activity	1
protein transmembrane transport	1
protein transporter activity	1
ribonucleoprotein complex binding	1
binding	1
translocon complex	1
cytoplasm	1
endomembrane system	1
intracellular membrane-bounded organelle	1
organelle membrane	1
nuclear outer membrane-endoplasmic reticulum membrane network	1
endoplasmic reticulum subcompartment	1
cellular anatomical structure	1

Protein interactions and networks

STRING

2565 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
SEC61A2	SEC61B	P38390	707
SEC61A2	SEC61G	P38384	643
SEC61A2	DDOST	P39656	643
SEC61A2	SEC63	Q9UGP8	522
SEC61A2	PMFBP1	Q8TBY8	484
SEC61A2	VPS33B	Q9H267	481
SEC61A2	TATDN3	Q17R31	478
SEC61A2	TMEM147	Q9BVK8	447
SEC61A2	SEC62	Q99442	443
SEC61A2	ALLC	Q8N6M5	425
SEC61A2	SRPRA	P08240	423
SEC61A2	CCDC47	Q96A33	422
SEC61A2	SRP54	P13624	422
SEC61A2	SPCS2	Q15005	420
SEC61A2	SRP19	P09132	410

IntAct

36 interactions, top by confidence:

A	B	Type	Score
CFTR	XPO1	psi-mi:“MI:0914”(association)	0.710
CFTR	ESYT2	psi-mi:“MI:0914”(association)	0.710
RAF1	CALU	psi-mi:“MI:0914”(association)	0.640
SEC61A2	SEC61B	psi-mi:“MI:0915”(physical association)	0.560
PTPN5	PGRMC1	psi-mi:“MI:0914”(association)	0.350
USP19		psi-mi:“MI:0914”(association)	0.350
SLC16A11	ESYT2	psi-mi:“MI:0914”(association)	0.350
ADCK2	ILVBL	psi-mi:“MI:0914”(association)	0.350
POMK	ESYT2	psi-mi:“MI:0914”(association)	0.350
CLN3	ESYT2	psi-mi:“MI:0914”(association)	0.350
RAF1	EIF3CL	psi-mi:“MI:0914”(association)	0.350
CCDC47	ESYT2	psi-mi:“MI:0914”(association)	0.350
SEC61B	RPS3A	psi-mi:“MI:0914”(association)	0.350
ATG16L1	ESYT2	psi-mi:“MI:0914”(association)	0.350
GPR182	SLC12A8	psi-mi:“MI:0914”(association)	0.350
TSPAN8	POTEF	psi-mi:“MI:0914”(association)	0.350
ASPH	POTEF	psi-mi:“MI:0914”(association)	0.350
OPALIN	FAM171A2	psi-mi:“MI:0914”(association)	0.350
MFSD4A	UBXN8	psi-mi:“MI:0914”(association)	0.350
SLC1A1	UBXN8	psi-mi:“MI:0914”(association)	0.350
AQP3	UBXN8	psi-mi:“MI:0914”(association)	0.350
SYP	HAS3	psi-mi:“MI:0914”(association)	0.350
VIPR1	SLC33A1	psi-mi:“MI:0914”(association)	0.350
ENTPD2	CLGN	psi-mi:“MI:0914”(association)	0.350
LRRN4CL	BTAF1	psi-mi:“MI:0914”(association)	0.350
TMEM192	EXTL3	psi-mi:“MI:0914”(association)	0.350
SLC15A2	LGALS8	psi-mi:“MI:0914”(association)	0.350

BioGRID (51): SEC61A2 (Affinity Capture-MS), SEC61A2 (Affinity Capture-MS), SEC61A2 (Affinity Capture-MS), SEC61A2 (Affinity Capture-MS), SEC61A2 (Affinity Capture-MS), SEC61A2 (Affinity Capture-MS), SEC61A2 (Synthetic Lethality), SEC61A2 (Affinity Capture-RNA), TOMM6 (Two-hybrid), SEC61A2 (Affinity Capture-MS), SEC61A2 (Affinity Capture-MS), SEC61A2 (Proximity Label-MS), SEC61A2 (Affinity Capture-MS), SEC61A2 (Proximity Label-MS), SEC61A2 (Affinity Capture-MS)

ESM2 similar proteins: A1C3L4, A3CK84, A3CM55, A6QKE2, A8AWV0, B2ISB6, B9DJQ6, D3HAJ5, D8MEB8, F0P5S5, F2QF13, F6CD01, F6CFW7, F8LHW1, F8LR08, P27148, P28527, P38377, P58118, P61619, P61620, P61621, P79088, Q2FUW2, Q2KHX4, Q2YZ90, Q3K059, Q4L9N9, Q54XK2, Q5EA68, Q5HCP4, Q5NVM7, Q5R5L5, Q74L41, Q7A363, Q7T277, Q7T278, Q8AY31, Q8AY32, Q8AY34

Diamond homologs: O26134, O28377, O59442, P28541, P28542, P32915, P38377, P38379, P49978, P61619, P61620, P61621, P78979, P79088, Q25147, Q2KHX4, Q54XK2, Q5EA68, Q5NVM7, Q5R5L5, Q60175, Q6BN08, Q6CPY9, Q6FRY3, Q752H7, Q7T277, Q7T278, Q870W0, Q8AY31, Q8AY32, Q8AY33, Q8AY34, Q8AY35, Q8AY36, Q8U019, Q90YL4, Q90ZM2, Q96TW8, Q977V3, Q98SN8

SIGNOR signaling

1 interactions.

A	Effect	B	Mechanism
SEC61A2	“form complex”	“SEC61 complex”	binding

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 48 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
SLC-mediated transmembrane transport	5	10.6×	8e-03
Transport of small molecules	7	6.3×	8e-03

GO biological processes:

GO term	Partners	Fold	FDR
ERAD pathway	5	22.1×	1e-03

Disease & clinical

Clinical variants and AI predictions

ClinVar

43 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	30
Likely benign	1
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

2708 predictions. Top by Δscore:

Variant	Effect	Δscore
10:12129790:GGGCA:G	donor_gain	1.0000
10:12129791:GGCA:G	donor_gain	1.0000
10:12129791:GGCAG:G	donor_gain	1.0000
10:12129792:GCA:G	donor_gain	1.0000
10:12129792:GCAG:G	donor_gain	1.0000
10:12129795:G:GG	donor_gain	1.0000
10:12133239:A:AG	acceptor_gain	1.0000
10:12133240:G:GA	acceptor_gain	1.0000
10:12133240:GT:G	acceptor_gain	1.0000
10:12133240:GTC:G	acceptor_gain	1.0000
10:12133240:GTCA:G	acceptor_gain	1.0000
10:12133240:GTCAA:G	acceptor_gain	1.0000
10:12133304:GGAAA:G	donor_gain	1.0000
10:12133305:GAAA:G	donor_gain	1.0000
10:12133305:GAAAG:G	donor_gain	1.0000
10:12133306:A:T	donor_gain	1.0000
10:12133306:AAA:A	donor_gain	1.0000
10:12133307:AA:A	donor_gain	1.0000
10:12133308:AG:A	donor_loss	1.0000
10:12133309:G:GG	donor_gain	1.0000
10:12133310:TAA:T	donor_loss	1.0000
10:12149722:GAAAC:G	donor_gain	1.0000
10:12149727:G:GG	donor_gain	1.0000
10:12149840:A:AG	acceptor_gain	1.0000
10:12149841:A:G	acceptor_gain	1.0000
10:12149850:A:AG	acceptor_gain	1.0000
10:12149851:G:GG	acceptor_gain	1.0000
10:12149851:GT:G	acceptor_gain	1.0000
10:12156040:GGGA:G	donor_gain	1.0000
10:12157904:TTAG:T	acceptor_loss	1.0000

AlphaMissense

3084 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
10:12136145:T:A	L39H	1.000
10:12136145:T:C	L39P	1.000
10:12136153:T:C	F42L	1.000
10:12136155:C:A	F42L	1.000
10:12136155:C:G	F42L	1.000
10:12136162:T:C	C45R	1.000
10:12143124:T:A	L50Q	1.000
10:12143129:G:A	G52R	1.000
10:12143129:G:C	G52R	1.000
10:12143130:G:A	G52E	1.000
10:12143153:G:C	D60H	1.000
10:12143172:G:C	R66T	1.000
10:12143172:G:T	R66I	1.000
10:12143184:C:A	A70D	1.000
10:12143186:T:C	S71P	1.000
10:12143187:C:T	S71F	1.000
10:12143195:G:A	G74R	1.000
10:12143195:G:C	G74R	1.000
10:12149595:G:A	G74E	1.000
10:12149595:G:T	G74V	1.000
10:12149598:C:T	T75I	1.000
10:12149606:G:A	E78K	1.000
10:12149612:G:A	G80S	1.000
10:12149612:G:C	G80R	1.000
10:12149612:G:T	G80C	1.000
10:12149613:G:A	G80D	1.000
10:12149613:G:T	G80V	1.000
10:12149622:C:A	P83Q	1.000
10:12149622:C:G	P83R	1.000
10:12149622:C:T	P83L	1.000

dbSNP variants (sampled 300 via entrez): RS1000003758 (10:12154125 T>C), RS1000078891 (10:12155218 G>A,C), RS1000203386 (10:12153917 C>A,T), RS1000311819 (10:12133557 G>A,C), RS1000323179 (10:12160671 G>A), RS1000360604 (10:12166007 G>A), RS1000443631 (10:12168303 C>A,T), RS1000502581 (10:12147626 A>G), RS1000525151 (10:12132336 A>T), RS1000630939 (10:12137347 G>A), RS1000719988 (10:12132364 A>G), RS1000893248 (10:12128027 G>A,C), RS1000955107 (10:12143420 G>A,T), RS1001024770 (10:12143652 G>T), RS1001058073 (10:12155538 A>G)

Disease associations

OMIM: gene MIM:618271 | disease phenotypes: MIM:174050

GenCC curated gene-disease

Mondo (1): autosomal dominant polycystic liver disease (MONDO:0000447)

Orphanet (1): Isolated polycystic liver disease (Orphanet:2924)

HPO phenotypes

1 total (1 of 1 shown, HPO-id order):

HPO	Term
HP:0006557	Polycystic liver disease

GWAS associations

0 associations (top):

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

21 total (human), top 21 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects cotreatment, decreases expression, affects expression, increases expression	5
Acetaminophen	increases expression	2
methylmercuric chloride	increases expression	1
triphenyl phosphate	affects expression	1
bisphenol A	decreases methylation	1
trichostatin A	affects expression	1
sodium arsenite	increases expression	1
cupric oxide	increases expression	1
di-n-butylphosphoric acid	affects expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, decreases expression	1
abrine	increases expression	1
dorsomorphin	decreases expression, affects cotreatment	1
Cadmium	decreases expression, increases abundance	1
Carbamazepine	affects expression	1
Doxorubicin	decreases expression	1
Methyl Methanesulfonate	increases expression	1
Phthalic Acids	decreases methylation	1
Testosterone	increases expression	1
Tobacco Smoke Pollution	increases expression	1
Cadmium Chloride	decreases expression, increases abundance	1
Okadaic Acid	increases expression	1

Clinical trials (associated diseases)

17 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT01157858	PHASE2	COMPLETED	Everolimus and LongActing Octreotide Trial in Polycystic Livers
NCT01670110	PHASE2	COMPLETED	Pasireotide LAR in Severe Polycystic Liver Disease
NCT02021110	PHASE2	COMPLETED	Ursodeoxycholic Acid as Treatment for Polycystic Liver Disease
NCT05478083	PHASE2	RECRUITING	A GnRH Agonist IN Pre-menopausal Women STudy to Treat Severe Polycystic Liver Disease
NCT00426153	PHASE2/PHASE3	COMPLETED	Octreotide in Severe Polycystic Liver Disease
NCT00565097	PHASE2/PHASE3	COMPLETED	Lanreotide as Treatment of Polycystic Livers
NCT00771888	PHASE2/PHASE3	UNKNOWN	Open-Label Extension of LOCKCYST Trial
NCT01315795	PHASE2/PHASE3	COMPLETED	Lanreotide Autogel in the Treatment of Symptomatic Polycystic Liver Disease
NCT05281328	PHASE2/PHASE3	ACTIVE_NOT_RECRUITING	A Trial to Assess the Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With PLD
NCT00934791	Not specified	TERMINATED	Polycystic Liver Disease in Kidney Transplant
NCT01354405	Not specified	COMPLETED	Somatostatin Analogues as a Volume Reducing Treatment of Polycystic Livers (RESOLVE)
NCT02173080	Not specified	COMPLETED	Development and Assessment of The Polycystic Liver Disease Questionnaire (PLD-Q).
NCT03960710	Not specified	UNKNOWN	Automatic Segmentation of Polycystic Liver
NCT04111692	Not specified	RECRUITING	A Prospective Observational Study of Foam Sclerotherapy .
NCT04645251	Not specified	RECRUITING	Polycystic Liver Disease Registry (UK)
NCT05215964	Not specified	UNKNOWN	The Association Between Skeletal Muscle Mass and Severity of Polycystic Liver Disease and Polycystic Kidney Disease
NCT05500157	Not specified	UNKNOWN	Assessment of Treatment With Laparoscopic Fenestration or Aspiration Sclerotherapy for Large Symptomatic Hepatic Cysts